“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome

We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of HRs in HER2 positive BC, we retrospectively identifie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Vici, Patrizia, Pizzuti, Laura, Sperduti, Isabella, Frassoldati, Antonio, Natoli, Clara, Gamucci, Teresa, Tomao, Silverio, Michelotti, Andrea, Moscetti, Luca, Gori, Stefania, Baldini, Editta, Giotta, Francesco, Cassano, Alessandra, Santini, Daniele, Giannarelli, Diana, Di Lauro, Luigi, Corsi, Domenico Cristiano, Marchetti, Paolo, Sini, Valentina, Sergi, Domenico, Barba, Maddalena, Maugeri-Saccà, Marcello, Russillo, Michelangelo, Mentuccia, Lucia, D'Onofrio, Loretta, Iezzi, Laura, Scinto, Angelo Fedele, Da Ros, Lucia, Bertolini, Ilaria, Basile, Maria Luisa, Rossi, Valentina, De Maria, Ruggero, Montemurro, Filippo
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2016
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4951261/
https://ncbi.nlm.nih.gov/pubmed/26910921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7480
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge